EP Learning Library
Core EP Topics

PVC-Induced Cardiomyopathy

Reversible cardiomyopathy caused by frequent premature ventricular complexes — diagnosis, risk factors, and ablation

PVC Burden Reversible CMP Catheter Ablation
1

Mechanism

Frequent premature ventricular complexes (PVCs) — typically exceeding 10–15% of total heartbeats over 24 hours — can cause a reversible dilated cardiomyopathy that is clinically indistinguishable from other forms of non-ischemic dilated cardiomyopathy (DCM). This entity, PVC-induced cardiomyopathy (PVC-CMP), is one of the most important reversible causes of heart failure, because elimination of the PVCs (by ablation or suppression) leads to substantial or complete recovery of LV function.

The pathophysiology of PVC-CMP mirrors that of pacing-induced cardiomyopathy. PVCs originating from the right ventricle or interventricular septum produce a dyssynchronous left ventricular contraction pattern similar to LBBB, with early septal activation and delayed lateral wall activation. This chronic dyssynchrony leads to:

  • Abnormal calcium handling: Chronic dyssynchronous activation disrupts intracellular calcium cycling, leading to reduced contractility and progressive myocardial dysfunction
  • Increased wall stress: The irregular timing of PVC beats (alternating between premature and post-extrasystolic beats) creates fluctuating hemodynamic loads that promote adverse remodeling
  • Neurohormonal activation: Reduced cardiac output from frequent PVCs triggers the renin-angiotensin-aldosterone system and sympathetic nervous system, accelerating the cardiomyopathic process
  • Tachycardia-mediated component: High PVC burdens effectively increase the average heart rate, contributing a tachycardia-mediated element to the cardiomyopathy
RISK FACTORS FOR PVC-INDUCED CARDIOMYOPATHY
  • High PVC burden: >15–20% of total beats (most important predictor)
  • Epicardial PVC origin: Wider QRS, more dyssynchronous activation
  • Interpolated PVCs: No compensatory pause → effectively higher burden and hemodynamic impact
  • Male sex: Higher risk at any given PVC burden
  • Longer PVC coupling interval: More hemodynamic disruption per beat
  • Retrograde VA conduction: Loss of AV synchrony with each PVC
  • PVC QRS duration >150 ms: Broader QRS = more dyssynchronous contraction
  • Multiple PVC morphologies or non-sustained VT runs

The PVC burden threshold for developing cardiomyopathy varies among individuals. While the classic teaching is >15–20%, some patients develop CMP with burdens as low as 10%, while others tolerate burdens of 25–30% without any decline in LV function. Individual susceptibility likely depends on genetic background, baseline cardiac reserve, PVC characteristics (morphology, coupling interval, interpolation), and the presence of co-existing cardiac disease. A key clinical principle: PVC-CMP is a diagnosis of exclusion confirmed by reversal — the definitive proof is improvement in LVEF after PVC elimination.

Clinical Pearl: PVC-CMP and coincidental PVCs in a patient with DCM can be difficult to distinguish. Both present with frequent PVCs and reduced LVEF. The distinguishing features favoring PVC-CMP include: (1) absence of LV scar on cardiac MRI (no late gadolinium enhancement), (2) global rather than regional LV dysfunction, (3) PVCs preceding the diagnosis of CMP, and (4) relatively preserved RV function. However, only PVC elimination with subsequent LVEF recovery confirms the diagnosis.
2

ECG Clues

The 12-lead ECG characteristics of the PVC itself are essential for two purposes: (1) risk-stratifying the potential for cardiomyopathy and (2) localizing the PVC origin to guide catheter ablation.

PVC Features Predictive of Cardiomyopathy

PVC ECG FEATURES ASSOCIATED WITH CMP RISK
  • LBBB morphology: RV or septal origin — produces the most dyssynchronous LV activation
  • QRS duration >150 ms: Broader PVC = greater dyssynchrony and mechanical disruption
  • Coupling interval >600 ms: Longer coupling intervals are more likely to be interpolated (no compensatory pause), increasing effective burden
  • Interpolated PVCs: The PVC is sandwiched between two sinus beats without a compensatory pause — the sinus cycle is not reset
  • Uniform morphology: A single dominant PVC morphology (monomorphic) is more amenable to ablation and may indicate a focal mechanism

PVC Origin Localization

Understanding PVC origin is critical for planning the ablation approach. The most common PVC origin causing cardiomyopathy is the right ventricular outflow tract (RVOT), accounting for 60–70% of idiopathic PVCs referred for ablation.

PVC Origin V1 Morphology Axis Precordial Transition Key Features
RVOT (septal) LBBB (QS or rS) Inferior (tall R in II, III, aVF) V3–V4 Most common idiopathic PVC. Tall R in inferior leads
RVOT (free wall) LBBB (QS) Inferior V4–V5 (later) Notched R in inferior leads, wider QRS than septal RVOT
LVOT / Aortic cusps RBBB or early transition Inferior V1–V2 (very early) Tall R in V1–V2, may mimic RVOT but transition is earlier. R/S ratio in V1 > 0.5
Left coronary cusp (LCC) LBBB or R/S ~1 in V1 Inferior V1–V3 Taller R in lead I than RVOT. W-pattern in V1. Close to left main coronary
Right coronary cusp (RCC) LBBB Inferior V3–V4 Very similar to RVOT. Distinguish by earlier transition and notching in V1–V2
Papillary muscle (LV) RBBB Variable Variable Multiple morphologies (PVC morphology variability). Often difficult to ablate (muscle trabeculation)
Mitral annulus RBBB Superior (inferoseptal) or inferior (lateral) Early to mid Prominent S in V6 (inferoseptal). May require retrograde aortic approach
Tricuspid annulus LBBB Left axis (free wall) or right axis (septal) Late Often well-tolerated, lower CMP risk

Key ECG features for RVOT vs. LVOT distinction (a common clinical dilemma): The V2 transition ratio (R/S amplitude during PVC divided by R/S during sinus rhythm) >0.6 favors an LVOT or aortic cusp origin. The V2S/V3R index (S-wave amplitude in V2 divided by R-wave in V3) >1.5 favors RVOT. Additionally, a prominent R-wave in lead I favors an LVOT origin (leftward initial vector), while an isoelectric or negative lead I favors RVOT.

Clinical Pearl: PVCs from the aortic cusps (particularly the left coronary cusp) can closely mimic RVOT PVCs on the 12-lead ECG. The critical distinction is the precordial transition — cusp PVCs have a very early transition (dominant R by V1–V2), while RVOT PVCs typically transition later (V3–V4). Misidentifying a cusp PVC as RVOT leads to fruitless mapping in the right ventricle. Always assess precordial transition carefully and consider cusp mapping when RVOT activation is late.
3

EP Study Findings

Pre-Procedural Evaluation

Before proceeding to EP study and ablation, a thorough non-invasive workup establishes the PVC burden, LV function, and scar burden:

PRE-ABLATION WORKUP
  • 24-hour Holter monitor: Quantifies PVC burden (total PVCs / total beats × 100). Key thresholds: >10% = consider evaluation; >15–20% with reduced EF = ablation indication. Also characterizes PVC morphology (monomorphic vs. polymorphic), coupling interval, and presence of NSVT
  • Echocardiography: LV dimensions, LVEF, regional wall motion. PVC-CMP typically shows global LV dilation without regional wall motion abnormalities (unlike ischemic CMP)
  • Cardiac MRI: Assess for structural disease. PVC-CMP: dilated LV with no or minimal late gadolinium enhancement (LGE). If significant LGE is present, consider primary CMP with coexistent PVCs rather than PVC-CMP
  • Coronary evaluation: Rule out ischemic heart disease, especially in patients with risk factors or regional WMA

EP Study During Ablation

The primary goal of the EP study is precise localization of the PVC origin for targeted ablation. The key strategies are:

Activation mapping during spontaneous PVCs: This is the most accurate approach when PVCs are frequent enough during the procedure (ideally >1 PVC per minute). The operator acquires a 3D electroanatomic map during sinus rhythm, then maps activation timing during PVCs. The site of earliest activation — the point with the most negative activation time relative to QRS onset — identifies the PVC focus. At the true origin, local activation typically precedes the QRS by 20–40 ms. A unipolar QS pattern at the earliest bipolar site provides additional confirmation.

Pace-mapping: At candidate sites, the operator paces at the mapping catheter and compares the paced 12-lead QRS morphology to the clinical PVC. A 12/12 lead match indicates the catheter is at or very near the PVC origin. Pace-mapping is particularly useful when PVCs are infrequent during the procedure (suppressed by sedation, anesthesia, or catheter manipulation). Automated pace-map correlation algorithms can provide quantitative match scores.

Site-Specific Mapping Considerations

RVOT mapping: The catheter is positioned in the right ventricular outflow tract, systematically surveying the septal, anterior, posterior, and free-wall aspects. RVOT PVC origins are most commonly posterior and septal, near the pulmonary valve plane. The earliest activation site (typically −25 to −40 ms pre-QRS) is the ablation target.

Aortic cusp mapping: Accessed via retrograde aortic approach. The catheter is positioned within the aortic root, below the level of the coronary ostia. The left coronary cusp (LCC) is adjacent to the left main coronary artery — coronary angiography or ICE must confirm >5 mm distance before ablation. The right coronary cusp (RCC) is the rightmost cusp, immediately above the RVOT. The LCC–RCC commissure is a common PVC origin.

Papillary muscle PVCs: These are among the most challenging PVCs to ablate. The papillary muscles (posteromedial and anterolateral) are thick, trabeculated structures with variable anatomy. PVCs from this location often exhibit morphology variability (slight changes in QRS from beat to beat) due to the complex geometry and multiple potential exit points. Catheter stability on the papillary muscle is poor, requiring careful mapping with ICE guidance and sometimes cryoablation for improved tissue contact.

Clinical Pearl: PVC suppression during the procedure is a common and frustrating problem — anesthesia, sedation, and catheter manipulation can eliminate PVCs entirely. Strategies to provoke PVCs include: (1) minimizing sedation (conscious sedation rather than general anesthesia when possible), (2) isoproterenol infusion (1–4 μg/min), (3) phenylephrine to increase afterload, and (4) burst ventricular pacing. If PVCs cannot be induced, rely on pace-mapping and the pre-procedural 12-lead PVC morphology.
4

Ablation Targets & Strategy

Indications for Ablation

  • Class I: PVC-induced cardiomyopathy (high burden + reduced LVEF) — catheter ablation to eliminate the PVC and allow LV recovery
  • Class I: Highly symptomatic PVCs refractory to or intolerant of medical therapy (beta-blockers, calcium channel blockers)
  • Class IIa: High PVC burden (>15–20%) with borderline or declining LVEF even without overt HF
  • Pre-ablation medical trial: Beta-blockers (metoprolol, carvedilol) or non-dihydropyridine CCBs (verapamil) should be trialed first, particularly for patients who prefer conservative management. Medical therapy rarely reduces PVC burden sufficiently to prevent CMP in high-burden patients

Ablation Approach by Site

RVOT ABLATION
  • Access: Femoral venous approach, catheter advanced to the RVOT
  • Target: Site of earliest activation (−20 to −40 ms pre-QRS) with unipolar QS morphology
  • Anatomy: Posterior/septal RVOT (most common), near pulmonary valve. Above the His bundle region — check for His potential before ablation to avoid AV block
  • Energy: Radiofrequency, 25–35 W, irrigated-tip catheter. Typical lesion: 60–90 seconds per application
  • Success rate: 85–95% acute success for RVOT PVCs — among the highest for any ablation target

LVOT / Aortic cusp ablation: Accessed via retrograde aortic approach (femoral arterial) or occasionally transseptal. The catheter is carefully positioned within the aortic root, and the earliest activation site is identified. Before delivering energy, coronary angiography or intracardiac echocardiography (ICE) must confirm that the ablation catheter is at least 5 mm from the left coronary artery ostium. Ablation in the aortic cusps is performed with lower power (20–30 W) and careful temperature monitoring to avoid aortic valve injury. Success rates are 80–90%.

Papillary muscle ablation: Accessed via retrograde aortic or transseptal approach for LV papillary muscles, or femoral venous for RV papillary muscles. The major challenge is catheter stability — the papillary muscles are mobile, trabeculated structures. Strategies include using ICE to guide catheter contact, employing steerable sheaths, and considering cryoablation (which adheres the catheter tip to tissue during energy delivery). Success rates are lower (60–75%) with higher recurrence than RVOT PVCs, and multiple procedures may be needed.

LV Recovery After Ablation

When PVCs are successfully eliminated, LV function improves dramatically. In true PVC-CMP:

  • Timeline: LVEF improvement begins within weeks and continues over 3–6 months. Most recovery occurs by 6 months
  • Magnitude: Average LVEF improvement of 10–15 percentage points. Many patients normalize LVEF completely (≥50%), particularly when PVC-CMP is caught early before extensive remodeling
  • LV dimensions: LV end-diastolic diameter typically normalizes in parallel with EF recovery
  • Confirmation of diagnosis: LVEF recovery after PVC elimination retrospectively confirms the diagnosis of PVC-CMP. If LVEF does not improve after documented PVC suppression/elimination, the cardiomyopathy was likely primary DCM with coincidental PVCs
Clinical Pearl: Do not confuse PVC-CMP with PVCs coincidental to DCM. In patients with structural heart disease, PVCs are common but may be a consequence rather than a cause of the cardiomyopathy. Ablation in these patients may reduce PVC burden but will not improve LVEF. Key distinguishing features: PVC-CMP → no LGE on MRI, global dysfunction, PVCs preceded CMP diagnosis. Coincidental PVCs + DCM → LGE present, regional WMA, CMP preceded or concurrent with PVC recognition.

Complications

  • RVOT perforation: The RVOT wall is thin (2–3 mm) — perforation with pericardial effusion/tamponade is the primary risk (0.5–1%). Use irrigated catheters carefully with power titration
  • Aortic valve injury: During cusp ablation, the catheter can traumatize a cusp, causing aortic regurgitation. Minimize catheter manipulation within the cusps and use low power
  • Coronary artery injury: Ablation near the aortic cusps risks thermal injury to the left main or RCA. Always confirm coronary distance before ablating
  • AV block: RVOT PVCs at the posteroseptal aspect are near the His bundle — document His location before ablation
  • PVC recurrence: 10–15% recurrence at 1 year for RVOT; higher for papillary muscle and epicardial origins. Repeat ablation is effective

Key References

  1. Bogun FM, Desjardins B, Crawford T, et al. Post-infarction ventricular arrhythmias originating in papillary muscles. J Am Coll Cardiol. 2008;51(18):1794-1802. DOI: 10.1016/j.jacc.2008.01.046
  2. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7(7):865-869. DOI: 10.1016/j.hrthm.2010.03.036
  3. Niwano S, Wakisaka Y, Niwano H, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart. 2009;95(15):1230-1237. DOI: 10.1136/hrt.2008.159558
  4. Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol. 2015;1(3):116-123. DOI: 10.1016/j.jacep.2015.04.005
  5. Ban JE, Park HC, Park JS, et al. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. Europace. 2013;15(5):735-741. DOI: 10.1093/europace/eus371
  6. Latchamsetty R, Morady F. Premature ventricular complex–induced cardiomyopathy. JACC Clin Electrophysiol. 2019;5(5):537-550. DOI: 10.1016/j.jacep.2019.03.013